Form 4: Oscar Health Executive Sells Shares

Oscar Health's President of Oscar Insurance, Janet Liang, has sold a significant number of Class A common stock shares.

Summary

• Janet Liang, President of Oscar Insurance, reported the sale of 8,940 shares of Class A Common Stock on June 2, 2026, at a weighted average price of $21.74 per share.
• An additional sale of 3,535 shares of Class A Common Stock was also reported on June 2, 2026, at a weighted average price of $22.45 per share.
• These transactions were executed as part of a Rule 10b5-1 instruction letter entered into on August 8, 2025, to manage tax withholding obligations upon the vesting of equity awards.
• Following these transactions, Liang beneficially owns 262,592 shares directly and 259,057 shares directly, with some of these shares to be issued upon vesting of restricted stock units.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the significant volume of shares sold by a key executive, despite the explanation provided.

Negatives

• Executive sale of a substantial number of shares could be perceived negatively by the market, although it is attributed to tax withholding obligations.

Risks

• The filing does not explicitly mention any new risks. However, the sale of shares by a key executive could be interpreted as a lack of confidence by some investors, potentially impacting share price.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions are related to prior equity awards and a pre-arranged trading plan.

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 instruction letter entered into on August 8, 2025, to satisfy the Reporting Person's tax withholding obligation upon the vesting of previously granted equity awards.
• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive.
• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.03 to $22.96, inclusive.

Industry Context

StockSavvy.ai notes that insider selling, even when explained by tax obligations or pre-arranged plans like Rule 10b5-1, can sometimes lead to short-term market scrutiny for health insurance companies like Oscar Health, especially if the volume is significant.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, potentially impacting short-term stock performance, despite the stated reason.
• Employees: May view the sale by a senior executive in the context of overall company performance and executive confidence.
• Management: The sale is a planned event to manage personal tax obligations, indicating a structured approach to executive compensation.

Next Steps

• The reporting person will continue to hold shares as per the beneficial ownership details provided.
• The Rule 10b5-1 plan will continue to be executed as per its terms.

Key Dates

Recommendation

The filing reports an insider sale, which can be a negative signal. However, the sale is attributed to a Rule 10b5-1 plan for tax withholding upon vesting, a common and often non-indicative reason for selling. Without further negative financial or operational news, a 'hold' recommendation is prudent, awaiting clearer signals of company performance.

Keywords

Oscar Health, OSCR, Form 4, Insider Trading, Stock Sale, Janet Liang, Class A Common Stock, Rule 10b5-1, Executive Compensation, Vesting